mRNA Lipid Nanoparticle Nebulization with TPGS Surfactant
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA-lipid nanoparticle compositions for pulmonary delivery face challenges in nebulization efficiency and encapsulation stability, with existing surfactants either being unsuitable or failing to improve nebulization properties without increasing particle size or reducing encapsulation efficiency.
Innovation Solution
Incorporating surfactants with an antioxidant moiety covalently linked to a PEG moiety, such as D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), at concentrations of at least 0.1% weight to volume, which maintains encapsulation efficiency and enhances nebulization output rates without significant particle size increase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional surfactants (Tween 20, Tween 80, PEG 400) are used to solubilize hydrophobic drugs, then solubilization capability is improved, but nebulization properties are either unsuitable or not improved
Solution Approach 1:
The patent changes the chemical structure parameters of the surfactant by using TPGS with specific molecular weight (1000 Da) and structure (amphiphilic with vitamin E head and PEG tail), which fundamentally alters the nebulization performance while maintaining solubilization capability
Solution Approach 2:
The invention creates a composite excipient system by combining the antioxidant vitamin E moiety with PEG linker and succinate group, forming TPGS which integrates multiple functions (surfactant, solubilizer, nebulization enhancer) in a single molecule
2Productivity
If surfactants are added to improve nebulization output rate, then nebulization efficiency is improved, but particle size increases
Solution Approach 1:
The patent optimizes the concentration parameter of TPGS to a specific range (0.01-5% w/v) and controls the PEG molecular weight (1-10 kDa) to achieve the desired balance between nebulization output and particle size control
3Productivity
If surfactants are added to enhance nebulization, then delivery efficiency is improved, but encapsulation efficiency is reduced
Solution Approach 1:
The patent carefully controls the concentration parameter of TPGS within 0.01-5% w/v range and adjusts the PEG molecular weight to maintain encapsulation efficiency while improving delivery
Solution Approach 2:
TPGS acts as an intermediary substance that mediates between the lipid nanoparticle and the nebulization process, improving delivery without compromising encapsulation by forming a stable interface
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these surfactants enables effective nebulization of mRNA-lipid nanoparticles with improved delivery to the lungs, ensuring intact mRNA expression and maintaining encapsulation efficiency, thereby enhancing the therapeutic efficacy of pulmonary mRNA delivery.
Implementation Method 1
TPGS finds use as a solubilizer, emulsifier, as well as a permeation and bioavailability enhancer of hydrophobic drugs... the inventors believe that TPGS and similar surfactants which consist of an antioxidant moiety covalently linked via a linker moiety to a PEG moiety provide a particular combination of properties that render them especially suitable as excipient to improve the nebulization output rate
Implementation Method 2
TPGS is a water-soluble derivative of natural vitamin E. It has an amphiphilic structure comprising a hydrophilic polar head portion and a lipophilic alkyl tail
Data Source
AI summary
The present invention provides, among other things, improved compositions comprising mRNA lipid nanoparticles and surfactants.